ASH25 Day 3: Don’t Miss The Highlights

The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.

It aims to bring together hematology professionals from across the globe.

Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.

Find the highlights from Day 3

Wolfgang Miesbach:

”iTTP and Pregnancy: Moving from “Contraindication” to “Careful Planning”

Is a history of immune-mediated TTP (iTTP) an absolute contraindication for pregnancy?

The answer from ASH25 is a resounding no—but it requires precision medicine and a team approach.

In the second part of his excellent education session, Dr. Senthil Sukumar (Baylor College of Medicine) tackled the complex landscape of pregnancy during remission.

Here are the critical clinical pearls for managing our patients who wish to conceive:

The Risks are Real but Manageable

We cannot sugarcoat the data. Complication rates remain high:

• Preeclampsia: ~28%
• Clinical Relapse: ~25%
• Miscarriage: ~18%

The “Pre-Conception” Window is Vital

Success starts months before conception.

Dr. Sukumar’s expert opinion suggests:
Check ADAMTS13 6–12 months prior to planned conception.
Target: If ADAMTS13 is <20%, consider preemptive rituximab and defer pregnancy for 6–12 months to ensure a safe baseline.

During Pregnancy: A Tiered Strategy
Management shouldn’t be static. The presented algorithm (adapted from Ferrari et al. and Brown et al.) proposes adapting therapy based on ADAMTS13 levels:

• >20-25%: Close monitoring (CBC and ADAMTS13 every 3-4 weeks).
• 10-20%: Consider low-dose steroids.
• <10%: Consider plasma exchange to prevent overt relapse.

Prophylaxis: Low-dose aspirin after 12 weeks is recommended (per USPSTF guidelines for high-risk preeclampsia).

The takeaway?

With a multidisciplinary team (Hematology + Maternal-Fetal Medicine) and enhanced monitoring, we can support our iTTP patients in building their families safely.

”

Marc Carrier:

”Congratulations to Dr. Mysa Saad on her first oral presentation at ASH25!

Does concurrent antiplatelet or NSAID use increase bleeding risk in cancer patients receiving apixaban thromboprophylaxis?

Key Findings:
• Among patients receiving prophylactic apixaban, concurrent antiplatelet/NSAID use significantly increased clinically relevant bleeding (HR 1.78) and CRNMB (HR 1.98).
• No reduction in VTE was observed (HR 0.60).
• In subgroup analyses:
– Antiplatelet agents were the main driver of increased bleeding (CRNMB HR 2.59).
– NSAIDs did not show a significant impact on bleeding or VTE.
• Mortality outcomes were unaffected.

Implications:

These results highlight the need to carefully reassess antiplatelet/NSAID indications and conduct individualized bleeding risk evaluations when considering apixaban prophylaxis in cancer outpatients.

”

John Strouse:

”John Belcher describes use of AT3 and C1 esterase inhibitor (C1-INH) concentrates on induced vaso-occlusion in sickle cell mice-dose réponse effect of AT3 and C1-INH and deposition of C3 in glomeruli

”

Akshat Jain:

”A day filled with remarkable science in clinical development for Sickle Cell Disease at the American Society of Hematology 2025 national meeting!

Using novel new ways to positively affect the Erythron, three new approaches were discussed :

1. Transcriptome guided novel target by affecting NED Dlyation through DCN1 pathway thereby augmenting fetal hemoglobin rise ,predicted to raise fetal hemoglobin close to gene therapy ranges by just an oral drug delivery platform.

2. Knockdown of G-CSF in Sickle cell Disease , hoping it will impact Netosis and vaso occlusion.

Thromboinflammation front and center.

Very complimentary to our work being done by the Sickle Cell Hemostasis Taskforce

3. Acute chest syndrome acute treatment by reduction of NETs

Additionally proud to have shared our clincial work on standadizing point of care testing with near 100% concordance with HPLC for all hemoglobinoapthies in the USA for the first time.

”

The Lancet Haematology:

”Just published online and presented at ASH25: EPCORE CLL-1

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Great presentation by Arnon P. Kater!

Read the full article here.

”

Marc Carrier:

”Huge congratulations to Dr. Abdulrahman Al Raizah on delivering his first ASH presentation!

His team’s quality-improvement project tackled two major challenges in IVC filter use: insertion without proper indication and delayed retrieval.

Through a coordinated, system-level strategy, they achieved:
• Appropriate filter use: 72.7% → 91.4%
• Retrieval among eligible patients: 76% → 92.3%
• Median retrieval time: reduced from 35 to 22 days

A fantastic example of how evidence-based policy, education, and workflow redesign can meaningfully improve thrombosis care.

”

Levine Cancer:

”Prenatal gene therapy for Hemophilia A shows promise!

In a sheep study, delivering AAV-based therapy before birth led to sustained FVIII levels for a year—far better than postnatal treatment.

”

Albert Bourla:

”More than 800,000 people worldwide live with hemophilia.

For those who develop inhibitors, standard treatments no longer work.

At ASH25, we presented Phase 3 data, published in  Blood Journals Portfolio, that could change that.

Grateful to our teams behind this remarkable science.”

Levine Cancer:

”New insight

MGUS can do more than signal plasma cell disorders—it may trigger Acquired Hemophilia A, a rare autoimmune attack on Factor VIII causing severe bleeding.

Heightened vigilance is key.

”

Alaa Hamed:

”This year, the Sanofi rare disease team is focused on driving meaningful progress in rare blood disorders through:

Deep scientific exchange advancing knowledge in hemophilia, ITP, and iTTP

Multiple poster presentations showcasing data from our research into rare blood disorders

Clinical trial recruitment initiatives across our rare blood disorder portfolio

A highlight was the STAR (Sanofi Trial Awareness and Recruitment) program on December 6th, designed to streamline clinical study engagement, strengthen healthcare professional partnerships, and enhance diverse patient enrolment through meaningful scientific collaboration.

Grateful to our distinguished expert speakers—Dr. Guy Young, Dr. Waleed Ghanima, and Dr. Biree Andemariam—for sharing valuable insights on Sanofi’s key clinical trials in Hemophilia, wAIHA, ITP and Sickle Cell Disease.

A special thank you to the exceptional Global Sanofi Medical Affairs team, including Shariq Ali, James Cobb, Jennifer Dumont, Monique Bidell, Lauriaselle Afanador, Sandra Casiano, Chase Lee, Marta Borchiellini, K. Amy Chen, Julie Kissell Pablo Manuel Bianculli Maria Belen Rodriguez Mario Aguiar Rahul Bohra Sequoia Baskind for making this impactful event possible.

Our US Medical Colleagues Brad Ward; Dina Issa and many others.

Our Medical Colleagues from around the globe Jasmine Chang, Kevin Chueh, Marlene Gharib, Özgur Pektas, BoSkjoedt Rafn, Aymeric Duvivier, Shinichi Nakamuta, Mark Surka, Yuka Tanaka, Haruhi Ando

”

More from ASH25 featured in Hemostasis Today.